Needle-free Vaccine Patches coming soon, easy to apply

The technique could help save children's tears at doctors' offices, and help people who have a phobia of syringes.

140

Last Updated on January 6, 2024 by The Health Master

Needle-free Vaccine Patches coming soon

Effective vaccines, without a needle: Since the start of the C-19 pandemic, researchers have doubled down on efforts to create patches that deliver life-saving drugs painlessly to the skin, a development that could revolutionize medicine.

The technique could help save children’s tears at doctors’ offices, and help people who have a phobia of syringes.

Beyond that, skin patches could assist with distribution efforts, because they don’t have cold-chain requirements – and might even heighten vaccine efficacy.

A new mouse study in the area, published in the journal Science Advances, showed promising results.

The Australian-US team used patches measuring one square centimeter that were dotted with more than 5,000 microscopic spikes, “so tiny you can’t actually see them,” David Muller, a virologist at the University of Queensland and co-author of the paper, told AFP.

These tips have been coated with an experimental vaccine, and the patch is clicked on with an applicator that resembles a hockey puck. “It’s like you get a good flick on the skin,” said Muller.

The researchers used a so-called “subunit” vaccine that reproduces the spikes that dot the surface of the coronavirus.

Mice were injected either via the patch over the course of two minutes, or with a syringe.

The immune systems of those who got the patch produced high levels of neutralizing antibodies after two doses, including in their lungs, vital to stopping C-19, and the patches outperformed syringes.

The researchers also found that a sub-group of mice, who were given only one dose of vaccine containing an additional substance called an adjuvant used to spur immune response, “didn’t get sick at all,” said Muller.

Easy to apply

Vaccines are normally injected into our muscles, but muscle tissue doesn’t contain very many immune cells needed to react to the drug, explained Muller.

In addition, the tiny spikes cause localized skin death, which alerts the body to a problem and triggers a greater immune response.

For the scientist, the logistical advantages couldn’t be clearer.

First, when dry-coated on a patch, the vaccine is stable for at least 30 days at 25 degrees Celsius (77 degrees Fahrenheit) and one week at 40C (104F), compared to a few hours at room temperature for the Moderna and Pfizer vaccines.

This offers a major advantage particularly for developing countries.

Second, “it’s very simple to use,” said Muller. “You don’t necessarily need highly trained medical professionals to deliver it.”

Burak Ozdoganlar, a professor of engineering at Carnegie Mellon University in the US city of Pittsburgh, has also been working on the technology since 2007.

He sees yet another advantage: “Less amount of vaccine delivered precisely to skin can activate an immune response similar to intramuscular injection,” he told AFP. It’s an important factor as the developing world struggles to procure enough C-19 vaccine.

Ozdoganlar can produce around 300-400 patches a day in his lab, but hasn’t been able to test them out on mRNA vaccines, which have come to the fore during the pandemic, because he hasn’t been authorized by Pfizer or Moderna.

The future

The patch used in the study published on Friday was made by Australian company Vaxxas, which is the furthest along. Human trials are planned from April.

Two other American companies are also part of the race: Micron Biomedical and Vaxess.

The latter, founded in 2013 and based in Massachusetts, is working on a slightly different type of patch, with microneedles that dissolve in the skin.

They say this approach has the benefit of requiring fewer spikes per patch — just 121 — made of a protein polymer that is biocompatible.

“We’re working on a seasonal C-19 and flu combination product that will be mailed directly to patients’ homes, for self-administration,” CEO Michael Schrader told AFP.

The C-19 vaccine they are using is produced by the company Medigen, already authorized in Taiwan.

Vaxess has just opened a factory near Boston, with funding from the US National Institutes for Health. They aim to produce enough patches to vaccinate 2,000 to 3,000 people in clinical trials, which are to be launched next summer.

The main challenge right now is production, with no manufacturers yet able to make enough patches en masse.

“If you want to launch a vaccine you have to produce hundreds of millions,” said Schrader. “We do not have that scale as of today — no one really has that scale.”

But the pandemic has given a push to the nascent industry, which is now attracting more investors, he added.

“This is the future, in my opinion, it is inevitable,” said Schrader. “I think you’re going to see over the next 10 years, this (will) pretty dramatically reshape the way that we get vaccines around the world.”

Govt issued notification for Form 29: License to Mfg drugs for…

DCGI nod for device-aided therapy for Parkinson’s patients

Dr Reddy’s to launch Clinical Trials of single dose Sputnik Light…

Serum Institute seeks DCGI Nod for Mfg Covid Vaccine Covovax

These Indian Pharma Cos seek nod from DCGI for marketing Anti…

NFI 2021: Salient features of 6th Edition of National Formulary of India

Indian Pharmacopoeia Commission (IPC)

Govt releases draft policy for R&D, Pharma and Medical Devices

Procedure to obtain license for manufacturing of Homoeopathic Medicines

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news